Ingress-health publishes results of a retrospective claims data analysis on MTX therapy adherence and persistence
MTX therapy is the recommended first-line treatment in rheumatoid arthritis (RA). However, it was not known how RA patients adhere to MTX treatment recommendations and what their persistence to therapy is. Ingress-health explored these questions by a retrospective analysis of German claims data. The analysis was unique in a sense that non-persistence and non-adherence were observed separately.
7,146 RA patients who received at least one MTX prescription (subgroup: 1,211 treatment-naïve patients) could be observed (mean age: 64.4 years, 73.6% female). Percentage of NP patients among MTX-naïve patients after 6, 12 and 18 months was 16.7%, 34.0% and 36.7%, respectively. During periods of general treatment continuation, the percentage of patients with a MPR<80% was 6.5%.
So, based on this analysis, it can be concluded that NP to MTX treatment seems to be common in one fourth of German RA patients. An additional number of patients, at least 6.5%, is also affected by NA.
The publication can be found here.